Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Published:2016-03-17 Issue:11 Volume:127 Page:1410-1416
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Viardot Andreas¹,Goebeler Marie-Elisabeth²,Hess Georg³,Neumann Svenja⁴,Pfreundschuh Michael⁵,Adrian Nicole⁵,Zettl Florian⁶,Libicher Martin⁷,Sayehli Cyrus²,Stieglmaier Julia⁸,Zhang Alicia⁹,Nagorsen Dirk⁹,Bargou Ralf C.¹⁰

Affiliation:

1. Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany;

2. Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany;

3. Department of Hematology, Oncology, and Pneumology, Johannes Gutenberg-University, Mainz, Germany;

4. Medical Department II, University Hospital Schleswig Holstein Campus Kiel, Kiel, Germany;

5. Klinik für Innere Medizin I, Saarland University Medical School, Homburg (Saar), Germany;

6. University Hospital Göttingen, Göttingen, Germany;

7. Department of Radiology, Diakoniekrankenhaus Schwäbisch-Hall, Schwäbisch-Hall, Germany;

8. Amgen Research (Munich), Munich, Germany;

9. Amgen Inc, Thousand Oaks, CA; and

10. Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany

Abstract

Key Points Among evaluable patients with relapsed/refractory DLBCL who received blinatumomab 112 μg/d, overall response was 43% (CR was 19%). Blinatumomab continuous infusion was feasible with weekly stepwise dose escalation (9-28-112 μg/d) and dexamethasone prophylaxis.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/11/1410/1392140/1410.pdf

Reference29 articles.

1. Anti-CD20 antibody therapy for B-cell lymphomas.;Maloney;N Engl J Med,2012

2. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).;Velasquez;Blood,1988

3. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma.;Moskowitz;J Clin Oncol,1999

4. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma.;Philip;N Engl J Med,1995

5. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.;Lazarus;Biol Blood Marrow Transplant,2010

Cited by 262 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma;Blood Advances;2024-02-13

2. Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-02

3. In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies;2024-01-31

4. New immune cell engagers for cancer immunotherapy;Nature Reviews Immunology;2024-01-25

5. A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment;Blood Advances;2024-01-23